IMMB
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2016 Q4 | -0.00 | $0 | — |
| 2016 Q3 | -0.00 | $0 | — |
| 2016 Q2 | -0.00 | $0 | — |
| 2006 Q3 | -1.00 | $0 | -$181,465 |
| 2006 Q2 | -0.35 | $0 | $105,732 |
| 2006 Q1 | -188.00 | $2,990 | -$177,088 |
| 2005 Q4 | 0.00 | $0 | -$165,357 |
| 2005 Q3 | -1942.00 | $0 | -$117,523 |